References
- Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lymphoma. Blood 2006;107:52–9.
- Hutchings M, Kostakoglu L, Zaucha JM, et al. In-vivo treatment sensitivity testing with PET/CT after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol 2014 July 28. [Epub ahead of print]
- Ree HJ, Kadin ME. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer 1985;56:333–338.
- Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma. J Clin Oncol 2009;27(15 Suppl.): Abstract 8528.
- Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362: 875–885.
- Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012;120:3280–3287.
- Touati M, Delage-Corre M, Monteil J, et al. CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. Leuk Lymphoma 2015;56:332–341.
- Khandani AH, Dunphy CH, Meteesatien P, et al. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009;30:594–601.